Literature DB >> 10448125

Effects of CYP1A2 on disposition of 2,3,7, 8-tetrachlorodibenzo-p-dioxin, 2,3,4,7,8-pentachlorodibenzofuran, and 2,2',4,4',5,5'-hexachlorobiphenyl in CYP1A2 knockout and parental (C57BL/6N and 129/Sv) strains of mice.

J J Diliberto1, D E Burgin, L S Birnbaum.   

Abstract

TCDD is the prototype and most potent member of the highly lipophilic polyhalogenated aromatic hydrocarbons (PHAHs), which are persistent and ubiquitous environmental contaminants. In both acute and subchronic animal studies, there is a specific accumulation of TCDD in liver greater than in adipose tissue. The inducible hepatic binding protein responsible for this hepatic sequestration of TCDD and its congeners has been shown by our laboratory to be CYP1A2 (J. J. Diliberto, D. Burgin, and L. S. Birnbaum, 1997, Biochem. Biophys. Res. Commun. 236, 431-433). The present study was conducted using knockout (KO) mice lacking expression of CYP1A2 (CYP1A2-/-) in order to investigate the role of CYP1A2 gene on the disposition of TCDD, 4-PeCDF (a dioxin-like PHAH), and PCB 153 (a nondioxin-like PCB) in KO (CYP1A2-/-) mice and age-matched parental mice strains (C57BL/6N: CYP1A2+/+, Ah(b/b) and 129/Sv: CYP1A2+/+, Ah(d/d)). Mice were dosed (25 microgram [(3)H]TCDD/kg, 300 microgram [(14)C]4-PeCDF/kg, or 35.8 mg [(14)C]PCB 153/kg bw in a corn oil vehicle) orally and terminated after 4 days. Residues of administered compounds in collected tissues and daily excreta were quantitated using (3)H or (14)C activity. Results demonstrated differential effects in disposition for the various treatments within the three genetically different groups of mice. In KO mice, TCDD, 4-PeCDF, and PCB 153 had very little hepatic localization of chemical, and the major depot was adipose tissue. In contrast, parental strains demonstrated hepatic sequestration of TCDD and 4-PeCDF, whereas disposition of PCB 153 in parental strains was similar to that in KO mice. Another difference between KO mice and parental strains was the enhanced urinary excretion of 4-PeCDF. This study demonstrates the importance of CYP1A2 in pharmacokinetic behavior and mechanistic issues for TCDD and related compounds. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10448125     DOI: 10.1006/taap.1999.8720

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  20 in total

1.  Atropselective Disposition of 2,2',3,4',6-Pentachlorobiphenyl (PCB 91) and Identification of Its Metabolites in Mice with Liver-Specific Deletion of Cytochrome P450 Reductase.

Authors:  Xianai Wu; Guangshu Zhai; Jerald L Schnoor; Hans-Joachim Lehmler
Journal:  Chem Res Toxicol       Date:  2019-08-26       Impact factor: 3.739

2.  Authentication of synthetic environmental contaminants and their (bio)transformation products in toxicology: polychlorinated biphenyls as an example.

Authors:  Xueshu Li; Erika B Holland; Wei Feng; Jing Zheng; Yao Dong; Isaac N Pessah; Michael W Duffel; Larry W Robertson; Hans-Joachim Lehmler
Journal:  Environ Sci Pollut Res Int       Date:  2018-01-10       Impact factor: 4.223

3.  Disruption of the gene for CYP1A2, which is expressed primarily in liver, leads to differential regulation of hepatic and pulmonary mouse CYP1A1 expression and augmented human CYP1A1 transcriptional activation in response to 3-methylcholanthrene in vivo.

Authors:  Weiwu Jiang; Lihua Wang; Sudha R Kondraganti; Inayat S Fazili; Xanthi I Couroucli; Edward A Felix; Bhagavatula Moorthy
Journal:  J Pharmacol Exp Ther       Date:  2010-08-23       Impact factor: 4.030

4.  Non-additive hepatic gene expression elicited by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and 2,2',4,4',5,5'-hexachlorobiphenyl (PCB153) co-treatment in C57BL/6 mice.

Authors:  Anna K Kopec; Michelle L D'Souza; Bryan D Mets; Lyle D Burgoon; Sarah E Reese; Kellie J Archer; Dave Potter; Colleen Tashiro; Bonnie Sharratt; Jack R Harkema; Timothy R Zacharewski
Journal:  Toxicol Appl Pharmacol       Date:  2011-08-07       Impact factor: 4.219

5.  The Influence of Obesity on the Pharmacokinetics of Dioxin in Mice: An Assessment Using Classical and PBPK Modeling.

Authors:  Claude Emond; Michael J DeVito; Janet J Diliberto; Linda S Birnbaum
Journal:  Toxicol Sci       Date:  2018-07-01       Impact factor: 4.849

6.  Hyper- and hypo-induction of cytochrome P450 activities with Aroclor 1254 and 3-methylcholanthrene in Cyp1a2(-/-) mice.

Authors:  Melissa L Barker; Laura B Hathaway; Dorinda D Arch; Mark L Westbroek; James P Kushner; John D Phillips; Michael R Franklin
Journal:  Chem Biol Interact       Date:  2009-09-20       Impact factor: 5.192

7.  Hypertension, cardiac hypertrophy, and impaired vascular relaxation induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin are associated with increased superoxide.

Authors:  Phillip G Kopf; Janice K Huwe; Mary K Walker
Journal:  Cardiovasc Toxicol       Date:  2008-10-11       Impact factor: 3.231

8.  3,3',4,4',5-Pentachlorobiphenyl (PCB 126) Decreases Hepatic and Systemic Ratios of Epoxide to Diol Metabolites of Unsaturated Fatty Acids in Male Rats.

Authors:  Xianai Wu; Jun Yang; Christophe Morisseau; Larry W Robertson; Bruce Hammock; Hans-Joachim Lehmler
Journal:  Toxicol Sci       Date:  2016-05-13       Impact factor: 4.849

9.  2,2',3,3',6,6'-Hexachlorobiphenyl (PCB 136) atropisomers interact enantioselectively with hepatic microsomal cytochrome P450 enzymes.

Authors:  Izabela Kania-Korwel; Eugene G Hrycay; Stelvio M Bandiera; Hans-Joachim Lehmler
Journal:  Chem Res Toxicol       Date:  2008-05-22       Impact factor: 3.739

10.  Hepatic P450 enzyme activity, tissue morphology and histology of mink (Mustela vison) exposed to polychlorinated dibenzofurans.

Authors:  Jeremy N Moore; John L Newsted; Markus Hecker; Matthew J Zwiernik; Scott D Fitzgerald; Denise P Kay; Xiaowei Zhang; Eric B Higley; Lesa L Aylward; Kerrie J Beckett; Robert A Budinsky; Steven J Bursian; John P Giesy
Journal:  Arch Environ Contam Toxicol       Date:  2009-05-21       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.